To evaluate the therapeutic potential of Emblica officinalis seed extract on ovalbumin-induced allergic asthma in Swiss Albino mice. The hydroalcoholic extract was prepared with seeds of Emblica officinalis (HAE). The seed extract was tested against ovalbumin (OVA)-induced allergic asthma in Swiss albino mice. The test medicines are given orally before being challenged with OVA aerosol 2.5% w/v. The levels of total and differential cell count, nitrite (NO2), and nitrate (NO3) are measured in bronchoalveolar lavage fluid (BALF) samples. Similarly, myeloperoxidase (MPO), malondialdehyde (MDA), and total lung protein (TLP) are measured in the lung tissue. Findings show that OVA-induced AHR significantly increases total and differential cell counts, NO2, and NO3. However, in a dose-dependent way, these parameters are considerably reduced in the HAE test group (HAE 50, 100, and 200 mg/kg). MPO, MDA, and total protein in the lungs all showed similar outcomes. The HAE at 200 mg/kg, however, demonstrated a notable restoration in every parameter, according to the mean value. AHR is known to be caused by pro-inflammatory mediators. The results of the histopathology support the efficacy of the HAE. According to the current research, Emblica officinalis seed extract has intriguing molecules for asthma research. Therefore, Emblica officinalis seed extract demonstrates promising anti-inflammatory and antioxidant effects in a preclinical model of allergic asthma, warranting further mechanistic and translational investigations.
